Ho Siu-Hong, Martin Francine, Higginbottom Adrian, Partridge Lynda J, Parthasarathy Varadarajan, Moseley Gregory W, Lopez Peter, Cheng-Mayer Cecilia, Monk Peter N
Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Avenue, 7th Floor, New York, NY 10016, USA.
J Virol. 2006 Jul;80(13):6487-96. doi: 10.1128/JVI.02539-05.
Human immunodeficiency virus type 1 (HIV-1) infection of human macrophages can be inhibited by antibodies which bind to the tetraspanin protein CD63, but not by antibodies that bind to other members of the tetraspanin family. This inhibitory response was limited to CCR5 (R5)-tropic virus and was only observed using macrophages, but not T cells. Here, we show that recombinant soluble forms of the large extracellular domain (EC2) of human tetraspanins CD9, CD63, CD81, and CD151 produced as fusion proteins with glutathione S-transferase (GST) can all potently and completely inhibit R5 HIV-1 infection of macrophages with 50% inhibitory concentration values of 0.11 to 1.2 nM. Infection of peripheral blood mononuclear cells could also be partly inhibited, although higher concentrations of EC2 proteins were required. Inhibition was largely coreceptor independent, as macrophage infections by virions pseudotyped with CXCR4 (X4)-tropic HIV-1 or vesicular stomatitis virus (VSV)-G glycoproteins were also inhibited, but was time dependent, since addition prior to or during, but not after, virus inoculation resulted in potent inhibition. Incubation with tetraspanins did not decrease CD4 or HIV-1 coreceptor expression but did block virion uptake. Colocalization of fluorescently labeled tetraspanin EC2 proteins and HIV-1 virions within, and with CD4 and CXCR4 at the cell surfaces of, macrophages could be detected, and internalized tetraspanin EC2 proteins were directed to vesicular compartments that contained internalized dextran and transferrin. Collectively, the data suggest that the mechanism of inhibition of HIV-1 infection by tetraspanins is at the step of virus entry, perhaps via interference with binding and/or the formation of CD4-coreceptor complexes within microdomains that are required for membrane fusion events.
与四跨膜蛋白CD63结合的抗体可抑制人巨噬细胞的1型人类免疫缺陷病毒(HIV-1)感染,但与四跨膜蛋白家族其他成员结合的抗体则无此作用。这种抑制反应仅限于CCR5(R5)嗜性病毒,且仅在巨噬细胞中观察到,在T细胞中未观察到。在此,我们表明,作为与谷胱甘肽S-转移酶(GST)融合蛋白产生的人四跨膜蛋白CD9、CD63、CD81和CD151的大细胞外结构域(EC2)的重组可溶性形式,均可有效且完全抑制巨噬细胞的R5 HIV-1感染,50%抑制浓度值为0.11至1.2 nM。外周血单个核细胞的感染也可部分受到抑制,尽管需要更高浓度的EC2蛋白。抑制作用在很大程度上不依赖共受体,因为用CXCR4(X4)嗜性HIV-1或水泡性口炎病毒(VSV)-G糖蛋白假型化的病毒粒子感染巨噬细胞也受到抑制,但具有时间依赖性,因为在病毒接种前或接种期间而非接种后添加会导致有效抑制。与四跨膜蛋白孵育不会降低CD4或HIV-1共受体的表达,但会阻断病毒粒子的摄取。可检测到荧光标记的四跨膜蛋白EC2蛋白与HIV-1病毒粒子在巨噬细胞内以及在细胞表面与CD4和CXCR4的共定位,内化的四跨膜蛋白EC2蛋白被导向含有内化葡聚糖和转铁蛋白的囊泡区室。总体而言,数据表明四跨膜蛋白抑制HIV-1感染的机制在于病毒进入步骤,可能是通过干扰膜融合事件所需微结构域内CD4-共受体复合物的结合和/或形成。